Hormone-independent prostate tumors, as well as neu+ (HER2-overexpressing) breast cancer tumors and neuroblastoma in animal models, have demonstrated sensitivity to 20, exhibiting an IC50 value of less than 1 μM. This evidence concerns the gene ERBB2 and breast carcinoma.